Aktienanalyse zu Odyssey Therapeutics Inc (ODTX)ODTXOdyssey Therapeutics Inc

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its advanced programs include OD-001, an oral small-molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, and OD-002, an oral small-molecule inhibitor of solute carrier family 15 member 4, or SLC15A4. These programs have the potential to yield treatments for inflammatory and autoimmune diseases. In addition to its advanced programs, it has a portfolio of preclinical programs that include a regulatory T cell, or Treg, -specific tumor necrosis factor receptor 2, or TNFR2, agonist, a bispecific antagonist of thymic stromal lymphopoietin, or TSLP, and interleukin-33, or IL-33, and an interleukin-1 receptor-associated kinase 4, or IRAK4, scaffolding inhibitor. It also has an interferon regulatory factor 5, or IRF5, inhibitor in preclinical development. It operates in the Healthcare sector.

Odyssey Therapeutics, Inc. is currently not a strong buy due to its recent performance and financial losses, despite having a promising pipeline and significant cash reserves. The current price is $19.00, with an RSI of 38.271 indicating potential oversold conditions. However, the company reported a net loss of $52.8 million in Q2 2026, which raises concerns about its short-term financial health.